Management Team

Ashley Van Zeeland, PhD

Co-Founder and Chief Executive Officer

Dr. Van Zeeland has been leading innovative scientific programs for the past 10 years, including groundbreaking work in the genetics of autism, and is an expert in large-scale sequencing studies. Read more

Previously she was Director, Strategic Partnerships at the Scripps Translational Science Institute (STSI) where she focused on novel public-private partnerships for translational science, including biomarker discovery. Dr. Van Zeeland oversees the overall scientific direction of Cypher Genomics and played a critical role in the initial commercialization of its technology. She received a Ph.D. in Neuroscience from the University of California, Los Angeles and MBA degree from the University of California, San Diego.

Adam Simpson

President and Chief Operating Officer

Mr. Simpson brings significant operational and emerging company experience to Cypher Genomics. Prior to his appointment as Cypher’s president and COO, Simpson served as an executive advisor to life science investors and companies including Cypher Genomics. Read more

Before that, Simpson was co-founder and chief business officer of Meritage Pharma from company creation through its acquisition by Shire, was the general counsel at Verus Pharmaceuticals where he led its sale to AstraZeneca and Shionogi, and previously was an attorney at Latham and Watkins. He holds a B.S. in biochemistry and cell biology from the University of California, San Diego and received a J.D. from the University of Minnesota Law School.

Ali Torkamani, PhD

Co-Founder and Chief Science Officer

Dr. Torkamani, an expert in genomic data analysis and interpretation with a strong focus in DNA sequence variation interpretation, is the lead inventor of Cypher Genomics’ genomic interpretation technology and Director of Genome Informatics and Drug Discovery at STSI. Read more

Dr. Torkamani is the lead investigator on validation studies of the Cypher Genomics’ technology, including in a clinical study at STSI to uncover the genetic cause of idiopathic disease (IDIOM). He holds a B.S. in Chemistry from Stanford University and a PhD in Biomedical Sciences from the University of California, San Diego.

Patrick Ravenel

Chief Technology Officer

Mr. Ravenel is a major contributor to the design, development and deployment of high-performance distributed computing solutions. His career has focused on high performance financial trading, commercial electronic data interchange (EDI), security, compliance and analytic systems. Read more

He was previously vice president of software development at MedImpact Healthcare Systems. Prior to MedImpact, he had successful exits (both acquisition and IPO) as a co-founder and a director in the areas of security and distributed transactional caching environments. In addition to his published papers, articles and book contributions, Mr. Ravenel has four patents in information security and automated compliance management. He holds a B.A. in Applied Mathematics and Scientific Programming from the University of California, San Diego.